$TherapeuticsMD (TXMD.US)$ @Tupack H McsnacksHi sir,how do ...

Mcsnacks H Tupack : Yea they didn’t Get approval so they can’t pay their bills now. Will have to do a reverse split and then an offering By February

Jiaxing99 OP Mcsnacks H Tupack : thanks for reply

MDR81 : you said earlier approval will be on 12th Dec Sunday.. what happened?

sayno : go read the news.

71302380 : TherapueticsMD still has a lot of potential, especially, at its current price range.  With their current 3 FDA approved products plus an FDA approved prenatal vitamin line, they are still positioned to receive at least 100 million in revenue in the next 12 months.  The FDA offered suggestions in their rejection of altering the current production of Annovera, so there is the posibility that the FDA could approve production changes in the future.  The company is still producing Annovera using the previous standards.  No reason to give up on TXMD yet.  TXMD will not be required to do reverse split until at least March 15th, but there are provisions to extend their listing on NASDAQ for another 3 to 6 months without a reverse split.  Additionally, there will be no need to do a reverse split if the share price exceeds a dollar again anyway.  There is at least one FDA approval still pending concerning low dose Bijuva.  Hopefully, that will be approved in March.  People shorting the stock would like people to believe that TXMD is dead, but that is far from the case yet.